These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 36704059)

  • 1. Asymptomatic Apical Hypertrophic Cardiomyopathy in an Elite Competitive Athlete.
    Huang AL; MacNamara J; Link MS; Martinez M; Dearani JA; Cannon BC; Levine BD; Ackerman MJ
    JACC Case Rep; 2023 Jan; 6():101705. PubMed ID: 36704059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Late Gadolinium Enhancement in Patients With Hypertrophic Cardiomyopathy and Preserved Systolic Function.
    Mentias A; Raeisi-Giglou P; Smedira NG; Feng K; Sato K; Wazni O; Kanj M; Flamm SD; Thamilarasan M; Popovic ZB; Lever HM; Desai MY
    J Am Coll Cardiol; 2018 Aug; 72(8):857-870. PubMed ID: 30115224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ESC sudden-death risk model in hypertrophic cardiomyopathy: Incremental value of quantitative contrast-enhanced CMR in intermediate-risk patients.
    Hinojar R; Zamorano JL; Gonzalez Gómez A; Plaza Martin M; Esteban A; Rincón LM; Portugal JC; Jimenez Nácher JJ; Fernández-Golfín C
    Clin Cardiol; 2017 Oct; 40(10):853-860. PubMed ID: 28614597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The value of cardiac magnetic resonance and distribution of late gadolinium enhancement for risk stratification of sudden cardiac death in patients with hypertrophic cardiomyopathy.
    Klopotowski M; Kukula K; Malek LA; Spiewak M; Polanska-Skrzypczyk M; Jamiolkowski J; Dabrowski M; Baranowski R; Klisiewicz A; Kusmierczyk M; Jasinska A; Jarmus E; Kruk M; Ruzyllo W; Witkowski A; Chojnowska L
    J Cardiol; 2016 Jul; 68(1):49-56. PubMed ID: 26363820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Predicting value of 2014 European guidelines risk prediction model for sudden cardiac death (HCM Risk-SCD) in Chinese patients with hypertrophic cardiomyopathy].
    Li WX; Liu LW; Wang J; Zuo L; Yang F; Kang N; Lei CH
    Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Dec; 45(12):1033-1038. PubMed ID: 29325362
    [No Abstract]   [Full Text] [Related]  

  • 6. The relationship between myocardial fibrosis detected by cardiac magnetic resonance and Tp-e interval, 5-year sudden cardiac death risk score in hypertrophic cardiomyopathy patients.
    Riza Demir A; Celik Ö; Sevinç S; Uygur B; Kahraman S; Yilmaz E; Cemek M; Onal Y; Erturk M
    Ann Noninvasive Electrocardiol; 2019 Sep; 24(5):e12672. PubMed ID: 31152489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy.
    Rubinshtein R; Glockner JF; Ommen SR; Araoz PA; Ackerman MJ; Sorajja P; Bos JM; Tajik AJ; Valeti US; Nishimura RA; Gersh BJ
    Circ Heart Fail; 2010 Jan; 3(1):51-8. PubMed ID: 19850699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term risk of sudden cardiac death in hypertrophic cardiomyopathy: a cardiac magnetic resonance outcome study.
    Greulich S; Seitz A; Herter D; Günther F; Probst S; Bekeredjian R; Gawaz M; Sechtem U; Mahrholdt H
    Eur Heart J Cardiovasc Imaging; 2021 Jun; 22(7):732-741. PubMed ID: 33458753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Applying Shared Decision Making to Sports Participation for a Patient With Hypertrophic Cardiomyopathy.
    de Feria AE; Lin KY; Day SM
    JACC Case Rep; 2021 Jan; 3(1):6-9. PubMed ID: 34317459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of late gadolinium enhancement on cardiac magnetic resonance in patients with hypertrophic cardiomyopathy.
    He D; Ye M; Zhang L; Jiang B
    Heart Lung; 2018; 47(2):122-126. PubMed ID: 29174363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Solving the Riddle of Sudden Cardiac Death in Hypertrophic Cardiomyopathy: The Added Role of Cardiac Magnetic Resonance.
    Stankowski K; Figliozzi S; Lisi C; Catapano F; Panico C; Cannata F; Mantovani R; Frontera A; Bragato RM; Stefanini G; Monti L; Condorelli G; Francone M
    J Cardiovasc Dev Dis; 2023 May; 10(6):. PubMed ID: 37367391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Importance of newer cardiac magnetic resonance-based risk markers for sudden death prevention in hypertrophic cardiomyopathy: An international multicenter study.
    Rowin EJ; Maron MS; Adler A; Albano AJ; Varnava AM; Spears D; Marsy D; Heitner SB; Cohen E; Leong KMW; Winters SL; Martinez MW; Koethe BC; Rakowski H; Maron BJ
    Heart Rhythm; 2022 May; 19(5):782-789. PubMed ID: 34933112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Benefit of Cardiac Magnetic Resonance Over Transthoracic Echocardiography for the Assessment of Ischemic and Nonischemic Dilated Cardiomyopathy Patients Referred for the Evaluation of Primary Prevention Implantable Cardioverter-Defibrillator Therapy.
    Pontone G; Guaricci AI; Andreini D; Solbiati A; Guglielmo M; Mushtaq S; Baggiano A; Beltrama V; Fusini L; Rota C; Segurini C; Conte E; Gripari P; Dello Russo A; Moltrasio M; Tundo F; Lombardi F; Muscogiuri G; Lorenzoni V; Tondo C; Agostoni P; Bartorelli AL; Pepi M
    Circ Cardiovasc Imaging; 2016 Oct; 9(10):. PubMed ID: 27729359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy.
    Chan RH; Maron BJ; Olivotto I; Pencina MJ; Assenza GE; Haas T; Lesser JR; Gruner C; Crean AM; Rakowski H; Udelson JE; Rowin E; Lombardi M; Cecchi F; Tomberli B; Spirito P; Formisano F; Biagini E; Rapezzi C; De Cecco CN; Autore C; Cook EF; Hong SN; Gibson CM; Manning WJ; Appelbaum E; Maron MS
    Circulation; 2014 Aug; 130(6):484-95. PubMed ID: 25092278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of the estimated 5-year risk of sudden cardiac death and syncope or non-sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy using late gadolinium enhancement and extracellular volume CMR.
    Avanesov M; Münch J; Weinrich J; Well L; Säring D; Stehning C; Tahir E; Bohnen S; Radunski UK; Muellerleile K; Adam G; Patten M; Lund G
    Eur Radiol; 2017 Dec; 27(12):5136-5145. PubMed ID: 28616729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular magnetic resonance imaging in hypertrophic cardiomyopathy: Current state of the art.
    Kamal MU; Riaz IB; Janardhanan R
    Cardiol J; 2016; 23(3):250-63. PubMed ID: 27064795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subclinical Hypertrophic Cardiomyopathy in Elite Athletes: Knowledge Gaps Persist.
    Chan F; Lockie T; Monserrat L; Moon JC; Captur G
    JACC Case Rep; 2022 Jan; 4(2):94-98. PubMed ID: 35106492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenotypic expression in hypertrophic cardiomyopathy and late gadolinium enhancement on cardiac magnetic resonance.
    Caetano F; Botelho A; Trigo J; Silva J; Almeida I; Venâncio M; Pais J; Sanches C; Leitão Marques A
    Rev Port Cardiol; 2014 May; 33(5):261-7. PubMed ID: 24909443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of cardiovascular magnetic resonance imaging for life-threatening arrhythmia detected by implantable cardioverter-defibrillator in Japanese patients with hypertrophic cardiomyopathy.
    Hen Y; Tsugu-Yagawa M; Iguchi N; Utanohara Y; Takada K; Machida H; Takara A; Teraoka K; Inoue K; Takamisawa I; Takayama M; Yoshikawa T
    Heart Vessels; 2018 Jan; 33(1):49-57. PubMed ID: 28766047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-Risk Apical Hypertrophic Cardiomyopathy Requiring an Implantable Cardioverter-Defibrillator: A Case Report of an Overlooked Etiology.
    Rathore A; Fortier JC; Chen K; Kadariya D; Catanzaro JN
    Cureus; 2023 Jul; 15(7):e41564. PubMed ID: 37565123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.